A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）

Starting soon · Early Phase 1

Conditions studied: Multiple Myeloma (MM)

In brief

This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory multiple myeloma.

Key facts

Study ID

NCT07399444

Run by

Institute of Hematology & Blood Diseases Hospital, China

People needed

38

Starts

2026-01-10

Expected to finish

2030-05-10

Last updated by the study team

2026-02-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects voluntarily participate in clinical studies; Fully informed of this study and signed informed consent; Informed consent form must be obtained prior to initiation of any study-related tests or procedures that are not part of the standard treatment for the subject's disease; Good compliance and cooperation with follow-up.
• Age ≥ 18 years.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Has measurable lesions
• Relapsed and/or refractory multiple myeloma
• Life expectancy≥ 3 months
• Clinical laboratory values meet screening visit criteria
• Adequate organ function.

You may not qualify if…

• Prior antitumor therapy with insufficient washout period ;
• Patients who are positive for hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C virus ribonucleic acid (HCV RNA), and human immunodeficiency virus antibody (HIV-Ab).
• Those who have experienced life-threatening allergic reactions, hypersensitivity reactions or intolerances to the excipients and related additives of the investigational drug; or those with a previous history of severe allergic reactions (such as hypersensitivity reactions, or those for whom the investigator assesses the need to use glucocorticoids to prevent severe immune-related reactions such as allergic reactions).
• Any condition deemed by the investigator as rendering the subject unsuitable for participation in this study.
• Also enrolled in other clinical studies.

Where it is running

• Henan Cancer Hospital — Zhengzhou, Henan, China
• Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei, China
• The Affiliated Hospital of Xuzhou Medical University — Xuzhou, Jiangsu, China
• The First Affiliated Hospital of Nanchang University — Nanchang, Jiangxi, China
• Beijing GoBroad Boren Hospital — Beijing, China
• Institute of Hematology & Blood Diseases Hospital — Tianjin, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.